Regeneron Pharmaceuticals Inc. (REGN) and Bayer HealthCare (BAYZF.PK, BAYRY.PK, BYR.L) announced that in the Phase 3 VISTA-DME trial of EYLEA (aflibercept) Injection for the treatment of diabetic macular edema, EYLEA 2 milligrams dosed monthly and EYLEA 2 mg dosed every two months showed a sustained improvement from baseline in best corrected visual acuity at week 100, compared to laser photocoagulation.
"These data showed that treatment with EYLEA in this trial improved vision and maintained the improvement over two years in patients with diabetic macular edema. These results are particularly encouraging given that 43 percent of patients in this study had previously received anti-VEGF therapy," said George Yancopoulos, Chief Scientific Officer of Regeneron and President of Regeneron Laboratories.
EYLEA was generally well tolerated in the trial with a similar overall incidence of adverse events, ocular serious adverse events, and non-ocular serious adverse events across the EYLEA treatment groups and the laser control group.
Bayer HealthCare and Regeneron are collaborating on the global development of EYLEA. Regeneron maintains exclusive rights to EYLEA in the United States. Bayer HealthCare licensed the exclusive marketing rights outside the United States, where the companies share equally the profits from sales of EYLEA, except for Japan where Regeneron receives a percentage on net sales.
For comments and feedback: editorial@rttnews.com